Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma.
atezolizumab plus bevacizumab therapy
hepatocellular carcinoma
therapeutic modifications
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
02 Mar 2023
02 Mar 2023
Historique:
received:
07
01
2023
revised:
20
02
2023
accepted:
27
02
2023
entrez:
11
3
2023
pubmed:
12
3
2023
medline:
12
3
2023
Statut:
epublish
Résumé
We retrospectively evaluated the impact of therapeutic modifications of atezolizumab (Atezo) plus bevacizumab (Bev) therapy (Atezo/Bev), including the interruption or discontinuation of both Atezo and Bev, and the reduction or discontinuation of Bev, on the outcome of patients with unresectable hepatocellular carcinoma (uHCC) (median observation period: 9.40 months). One hundred uHCC from five hospitals were included. Therapeutic modifications without discontinuation of both Atezo and Bev (
Identifiants
pubmed: 36900359
pii: cancers15051568
doi: 10.3390/cancers15051568
pmc: PMC10001232
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : the Kumamoto University Hospital Young Researcher Activation Project
ID : R4-13
Organisme : the Research Program on Hepatitis from the Japan Agency for Medical Research and Development
ID : AMED JP21fk0210048
Organisme : the Research Program on Hepatitis from the Japan Agency for Medical Research and Development
ID : AMED JP22fk0210103).
Déclaration de conflit d'intérêts
Y.T. received grants from Gilead Sciences, Fujirebio Inc. and Sysmex Corp., and lecture fees from Gilead Sciences, Takeda pharmaceutical company and Chugai pharmaceutical Co. The other authors have no conflict of interest to declare.
Références
Radiol Med. 2022 Feb;127(2):129-144
pubmed: 35028886
Cancer Med. 2021 Aug;10(16):5437-5447
pubmed: 34189869
J Clin Oncol. 2017 Mar;35(7):785-792
pubmed: 28068177
J Clin Oncol. 2022 Aug 20;40(24):2763-2773
pubmed: 35649192
Cancer Med. 2019 Jul;8(8):3719-3728
pubmed: 31127698
Dig Dis. 2015 Oct;33(6):751-8
pubmed: 26488473
Liver Int. 2021 Sep;41(9):2233-2234
pubmed: 34288369
Hepatology. 2018 Jan;67(1):358-380
pubmed: 28130846
Hepatol Res. 2022 Jan;52(1):105-119
pubmed: 34626450
Front Oncol. 2021 Jan 07;10:601240
pubmed: 33585218
Clin Cancer Res. 2022 Aug 15;28(16):3443-3451
pubmed: 34907081
Cancers (Basel). 2022 Sep 01;14(17):
pubmed: 36077816
J Hepatol. 2022 Apr;76(4):862-873
pubmed: 34902530
Hepatol Res. 2022 May;52(5):462-470
pubmed: 35080087
Hepatology. 2018 Aug;68(2):723-750
pubmed: 29624699
Nat Cancer. 2022 Apr;3(4):386-401
pubmed: 35484418
Liver Cancer. 2022 May 10;11(3):185-191
pubmed: 35949296
J Clin Oncol. 2021 Dec 20;39(36):4073-4126
pubmed: 34724392
Gut. 2023 Jan;72(1):129-140
pubmed: 35197323
J Clin Oncol. 2008 Jun 20;26(18):2992-8
pubmed: 18565886
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
J Hepatol. 2020 Feb;72(2):288-306
pubmed: 31954493
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Hepatology. 2022 Oct;76(4):1000-1012
pubmed: 35313048